SynthesisMolecular psychiatry2026
Global lifetime prevalence of schizophrenia: A systematic review and meta-analysis.
Synthesis in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Psychosocial Interventions, Recovery, and Mediating Mechanisms in Schizophrenia-Spectrum Disorders: A Systematic Review and Meta-Analysis of Longitudinal Studies.Brain sciences · 2026Review
- Metacognition and Self-Disturbances in Schizophrenia: Implications for Psychological and Neurocognitive Therapy.Brain sciences · 2026Review
- Errors or Adaptations? A Critical Review of Predictive Processing in Psychiatry.Behavioral sciences (Basel, Switzerland) · 2026Review
- Article
- Attitudes towards Tourette syndrome and schizophrenia amongst psychology students.Frontiers in psychology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrently, studies on the lifetime prevalence of schizophrenia in the general population have not been updated or limited to a single country or region. The lifetime prevalence of schizophrenia may differ in other populations with certain relevant influencing factors or conditions. Globally, there is a lack of meta-analyses focusing on the lifetime prevalence of schizophrenia in specific populations. This study aims to determine the lifetime prevalence of schizophrenia in the general population, homeless populations, offenders, populations with comorbid mental disorders, populations with comorbid physical illnesses, populations at high genetic risk, populations exposed to stress, low-income populations, and indigenous populations, and to identify relevant factors.
methodsMeta-analysis was used to estimate the combined lifetime prevalence of schizophrenia in the general population and eight other groups. To explore the sources of heterogeneity and identify factors associated with changes in prevalence, we conducted subgroup analyses of the general population, the homeless population, and the criminal population, examining geographic regions, sociodemographic factors, and methodological characteristics. Meta-regression in the general population examined the relationship between schizophrenia and mean age, publication year, and bias risk.
results109 articles were included. Among them, 60 reported results from a sample of 20,910,871 individuals from the general population across 24 countries, 21 involved 6,605 individuals from the homeless population in 11 countries, there were 36 studies involving seven different population groups. The lifetime prevalence of schizophrenia is 0.62% (95% CI [0.51%-0.76%]) in the general population and 10.02% (95% CI [7.38%-13.47%]) in the homeless populations. Asia has the lowest lifetime prevalence of schizophrenia in both the general population and the homeless population, at 0.47% (95% CI [0.35%-0.64%]) and 4.68% (95% CI [2.11%-10.07%]).
conclusionsFindings indicate that schizophrenia is more prevalent in special populations than in the general population. Understanding and addressing the risk factors contributing to elevated prevalence in vulnerable populations is essential for developing targeted prevention strategies and improving early intervention efforts.
Indexed as
Identifiers
41872519What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.